Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2018 Aug;72(2):302-308.
doi: 10.1053/j.ajkd.2017.11.015. Epub 2018 Feb 1.

The Value of Genetic Testing in Polycystic Kidney Diseases Illustrated by a Family With PKD2 and COL4A1 Mutations

Collaborators, Affiliations
Case Reports

The Value of Genetic Testing in Polycystic Kidney Diseases Illustrated by a Family With PKD2 and COL4A1 Mutations

Emilie Cornec-Le Gall et al. Am J Kidney Dis. 2018 Aug.

Abstract

The diagnosis of autosomal dominant polycystic kidney disease (ADPKD) relies on imaging criteria in the setting of a positive familial history. Molecular analysis, seldom used in clinical practice, identifies a causative mutation in >90% of cases in the genes PKD1, PKD2, or rarely GANAB. We report the clinical and genetic dissection of a 7-generation pedigree, resulting in the diagnosis of 2 different cystic disorders. Using targeted next-generation sequencing of 65 candidate genes in a patient with an ADPKD-like phenotype who lacked the familial PKD2 mutation, we identified a COL4A1 mutation (p.Gln247*) and made the diagnosis of HANAC (hereditary angiopathy with nephropathy, aneurysms, and muscle cramps) syndrome. While 4 individuals had ADPKD-PKD2, various COL4A1-related phenotypes were identified in 5 patients, and 3 individuals with likely digenic PKD2/COL4A1 disease reached end-stage renal disease at around 50 years of age, significantly earlier than observed for either monogenic disorder. Thus, using targeted next-generation sequencing as part of the diagnostic approach in patients with cystic diseases provides differential diagnoses and identifies factors underlying disease variability. As specific therapies are rapidly developing for ADPKD, a precise etiologic diagnosis should be paramount for inclusion in therapeutic trials and optimal patient management.

Keywords: Autosomal dominant polycystic kidney disease (ADPKD); COL4A1; HANAC; PKD2; case report; genetic testing; pedigree; phenotypic variability; targeted next-generation sequencing (TNGS).

PubMed Disclaimer

Figures

Figure 1
Figure 1. Molecular and imaging data for Pedigree M625 with ADPKD-PKD2 and COL4A1-associated diseases
A. Disease segregation in pedigree M625. Black symbols denote ADPKD-PKD2 affected individuals, blue symbols denote patients with COL4A1-associated diseases, and gray shading is used when the status of the individuals is unknown. Blue and black symbols are used in individuals with suspected digenic COL4A1-PKD2 disease. Slash over symbols denotes death. Genetic results were not available in III.2, IV.1, IV.3 but their status could be inferred from their medical records (IV.1 and IV.3) and/or from the dominant inheritance pattern of both diseases (III.2, IV.1, IV.3) (inferred genotype within parentheses). Subject II.1, who died at 63y, had a positive familial history of ADPKD (The ADPKD-affected descendants of II.4 are represented on the pedigree, and live in Europe, but no further information is available). Whether he also carried the COL4A1 variant is uncertain. Subject III.2 died at 46y from uremia; she was likely carrying both variants that she passed on to IV.1 and IV.3; for her husband (III.1), who died at age 72, no relevant past medical history was mentioned. B. IGV (integrative genomics viewer, Broad Institute) view of the next-generation sequencing of IV.6 shows COL4A1 variant c.739C>T (p.Gln247*) (reverse strand). Read depth: 2822, C=49%, T=51%. C. Sanger sequencing confirmation of heterozygous COL4A1 variant c.739C>T (p.Gln247*) in V.5, and PKD2 variant c.715_718dupTACG in VI.3. The wild-type sequences are shown for comparison. D. MRI, T2 weighted, of the COL4A1 subject V.5, 61y, showing bilateral renal cysts without kidney enlargement (HtTKV=200ml/m). E. MRI, T2 weighted, of PKD2 patient VI.1 at 53y, showing enlarged polycystic kidneys (HtTKV=1953 ml/m). F. MRI, T2, of PKD2 patient VI.2, who has moderately enlarged polycystic kidneys at 46y (HtTKV=470ml/m). G. MRI, T2, of COL4A1 individual VI.4 who has non-enlarged kidneys at 35y, with six cysts in the left kidney (the largest shown here measures 1.6 cm) and two millimeter sized cysts in the right kidney. H. Cerebral MRI of COL4A1 subject V.5, Axial FLAIR (fluid-attenuated inversion recovery) sequence demonstrating bilateral areas of signal hyperintensity in the centra semiovale (arrows). I. Cerebral MRI in COL4A1 subject VII.1 (4y), sagittal T1 weighted sequence showing marked volume loss in the superior cerebellar vermis (arrows).

References

    1. Ong AC, Devuyst O, Knebelmann B, Walz G Diseases E-EWGfIK. Autosomal dominant polycystic kidney disease: the changing face of clinical management. Lancet. 2015;385:1993–2002. - PubMed
    1. Cornec-Le Gall E, Audrezet MP, Rousseau A, et al. The PROPKD Score: A New Algorithm to Predict Renal Survival in Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol. 2016;27:942–951. - PMC - PubMed
    1. Heyer CM, Sundsbak JL, Abebe KZ, et al. Predicted Mutation Strength of Nontruncating PKD1 Mutations Aids Genotype-Phenotype Correlations in Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol. 2016;27:2872–2884. - PMC - PubMed
    1. Porath B, Gainullin VG, Cornec-Le Gall E, et al. Mutations in GANAB, Encoding the Glucosidase IIalpha Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease. Am J Hum Genet. 2016;98:1193–1207. - PMC - PubMed
    1. Besse W, Dong K, Choi J, et al. Isolated polycystic liver disease genes define effectors of polycystin-1 function. J Clin Invest. 2017;127:1772–1785. - PMC - PubMed

Publication types